Nephron

  • Sam Patrick posted an article
    Nephron partnership helps patients receive anesthetics faster see more

    A new partnership between Nephron Pharmaceuticals Corp. and National Medical Products Inc. will help provide more patients with a quick and simple delivery of anesthetic medications, according to a news release from Nephron.

    National Medical Products is the developer of the single-use, subcutaneous J-Tip Needle-Free Injector. Hospitals which use the injector will now be able to use Nephron-developed technology in a Luer lock syringe, buffered and pre-filled with lidocaine, to fill it.

    “This new partnership is a huge win for patients, and we are extraordinarily excited to announce it,” Lou Kennedy, CEO of West Columbia-headquartered Nephron, said in the release. “Working together with the developers of J-Tip, we are making sure that the delivery of anesthetic medications is safe, easy-to-use and virtually pain-free, because patients deserve nothing less.”

    California-based National Medical Products, established in 2001, refined a jet-injection technology previously used by the military for vaccine delivery to create a self-contained injector that uses compressed carbon dioxide to provide an anesthetic effect in one to two minutes, according to the release. The injector is most commonly used before procedures such as IV insertions and blood draws.

    Nephron said the companies hope the partnership will help reach more patients.

  • Sam Patrick posted an article
    USC Research partnerships generating big impact for state see more

    When the University of South Carolina’s Office of Economic Engagement (OEE) first launched six years ago, its goal was to build relationships between researchers and industry partners. True to its mandate, the university has forged ties with global industry giants and is driving hundreds of millions of dollars into the state’s economy.

    The OEE, with its corporate and government partners, has created over $790 million in indirect economic impact since its founding in 2013, using a standard economic development analysis that examines both direct and indirect economic benefits generated through the office. The figure includes ongoing industry partner investments along with grant generation, software gifts, and new job creation.

    “Thanks to the vision of President Harris Pastides, OEE has had a swift economic impact on our state,” said University of South Carolina president Robert Caslen. “We look forward to building more research partnership opportunities, and providing our students with the skills and expertise needed for success in high-tech careers.”

    The OEE serves as the convergence point for private industry, government and the university. In addition to connecting industry partners with the university’s intellectual capital, it also leads technology commercialization efforts, fosters entrepreneurship and start-ups, supports research centers, and grows existing collaborations.

    “The tremendous success we’ve had in such a short period of time is a testament to the quality of research taking place here at the University of South Carolina,” said OEE Executive Director Bill Kirkland. “We are in the top one percent of patent-producing universities in the world, and innovative industry leaders know that South Carolina is the place to be.”

    Ongoing research partnerships include a wide range of companies and federal agencies, from advanced computing, aerospace and automotive, to health care. They include: IBM, Boeing, NASA, Samsung, Siemens, Yaskawa, Capgemini, Prisma Health, Nephron, TIGHITCO and more.

    OEE supported research centers include:

    Three labs located at the McNAIR Aerospace Research Center on Catawba Street:

    The IBM IOT Industrial Innovation Center (2018). The only university based IBM lab of its kind in North America, the lab uses cloud data to develop new technolgoies to help American manfacturers improve their operations.

    The Digital Transformation Lab (2018). The 15,000 square-foot lab serves as a research showplace where projects with an array of real-world industrial and consumer applications are on display—from robotics, visual inspection, and autonomous drones to smart home appliances.

    The Center for Predictive Maintenance. Researchers and students from four university departments support the U.S. Army Aviation program Using cloud-based technology and machine learning, researchers and students use the technology to conduct detailed analyses, identify potential defects or problems, and recommend specific solutions to improve maintenance for combat helicopters.

    Siemens Healthineers Innovation Think Tank (ITT) Lab (2019). The ITT Lab is the first of its kind affiliated with a U.S. university.  The lab will be an innovation hub where participants including researchers, faculty members, and students can think outside the box to solve issues in healthcare, artificial intelligence, robotics, and information technology alongside industry innovation leaders. 

    The AI Institute (2019). The new institute advances state-of-the-art AI applications in fields like health care, education, social sciences, communications, advanced manufacturing, autonomous transportation, and personalized security, while also examining the ethics and societal impact of advancing technologies.

  • Sam Patrick posted an article
    Nephron, Clemson partner to meet hospital needs see more

    Nephron Pharmaceuticals Corporation is partnering with Clemson University to create a robotic solution for syringe-filling automation to enhance sterile manufacturing in the pharmaceutical production process and keep up with growing hospital demands.

    “We are excited about our new partnership with Clemson and we cannot wait to get started,” said Nephron CEO Lou Kennedy. “Working together with Clemson’s world-class researchers and engineers we can ensure that the pharmaceutical manufacturing process remains safe and we can deliver life-saving drugs to patients and hospitals across the country.”

    The university’s newest strategic partner is turning to Clemson to harness the power of technology for more efficient processes. To do so, Nephron is enlisting the expertise of the College of Engineering, Computing and Applied Sciences professor and researcher Yue “Sophie” Wang and mechanical engineering doctoral student Brandon Delspina and mechanical engineering master’s student Yu “Gloria” Zhang.

    Their robotics research for syringe automation will support the Nephron 503B Outsourcing Facility, a cGMP manufacturer providing sterile, pre-filled medications to address persistent drug shortages in hospitals and medical facilities across America.

    Based in West Columbia, Nephron is a certified woman-owned business and one of the fastest-growing companies in South Carolina. This is Nephron’s first partnership with the university and was developed through External Affairs’ Office of Corporate Partnerships and Strategic Initiatives at Clemson University.

    “When the External Affairs’ Office of Corporate Partnerships and Strategic Initiatives approached us about this project we were excited to get involved,” said Wang, associate professor of mechanical engineering. “Our work in robotics can have a tremendous impact on individuals across the country and we are looking forward to working on this because of its benefits for the many patients Nephron serves.”

    “Industry needs are changing at a rapid rate and Clemson is equipped to support companies like Nephron. Together, we have created a mutually beneficial project to enhance their capabilities while providing the university’s students with unique, hands-on research experience,” said Angie Leidinger, vice president for External Affairs. “This partnership is a testament to the work happening at Clemson and we’re looking forward to this collaboration, which will advance their business and benefit South Carolinians.”

  • Sam Patrick posted an article
    Nephron advances let it deliver supplies to hospitals faster than ever see more

    Nephron Pharmaceuticals Corp., headquartered in West Columbia, has announced the implementation of a microbial testing tool that the generic respiratory medication manufacturer says will help it deliver medical supplies to hospitals faster than ever.

    Growth Direct, developed by Massachusetts-based lab equipment supplier Rapid Micro Biosystems, automates the incubation, colony counting and data entry of microbial environment testing, according to a Nephron news release. The tool also detects microbial growth 50% faster than human eye.

    “We work hard, day in and out, to deliver safe, effective and affordable life-saving medications as efficiently as possible,” Nephron CEO Lou Kennedy said in the release. “Automating our microbial monitoring process allows us to produce safer drugs faster and decreases the shortage of opioid-free pain medication currently facing our nation’s hospitals.”

    Growth Direct will allow Nephron’s 503(b) outsourcing division, which produces pre-filled sterile syringes and IV bags, to deliver medical supplies more quickly, the release said.

    “We're excited that Nephron Pharmaceuticals Corp. has joined the growing list of global pharmaceutical manufacturers who are upgrading and automating their QC Microbial testing methods with the Growth Direct,” Rapid Micro Biosystems CEO Rob Spignesi said. “And we are proud to help Nephron Pharmaceuticals reduce the shortage of important drugs that help make surgery safer and less painful for patients across the country.”

  • Sam Patrick posted an article
    SCBIO and Nephron Pnarma executive Lou Kennedy honored by E&Y see more

    WEST COLUMBIA, S.C., June 28, 2019 /PRNewswire/ -- Ernst & Young (EY) honored Nephron Pharmaceuticals President and CEO Lou Kennedy as Health Care Entrepreneur of the Year for the Southeast on Thursday during a gala at the Coca-Cola Roxy in Atlanta. Kennedy, who is Chairman of the South Carolina Chamber of Commerce and of SCBIO, and a nationwide leader in health care, will now compete for the EY national entrepreneur of the year award in November.

    "I am grateful that EY recognizes the hard work our team does every day to deliver safe, effective and affordable drugs to patients, focusing on opiod-free pain treatment," said Kennedy. "As president of a global leader in life-saving drug manufacturing, I hope this award serves as a reminder that women are leading the fight to improve lives across the country and world, and at Nephron, like so many women-owned businesses, we are just getting started."

    Business leaders consider the EY entrepreneur of the year award to be one of the highest professional honors a business owner can earn. The award identifies leaders of fast-growth companies who are making a difference for their communities and beyond through innovation. 

    Nephron is a certified woman-owned business, as recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises. The certification gives Nephron enhanced visibility and a competitive edge.

    The Nephron workforce is forty-four percent women, holding the majority of all advanced degrees at the company. Additionally, women hold key management roles in various departments throughout Nephron, such as Quality Assurance, Chemistry and Microbiology, Regulatory Compliance, Human Resources, Training, R&D Engineering, and Product Development.

    About Nephron
    Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

  • Sam Patrick posted an article
    Nephron CEO and SCBIO Chair Lou Kennedy interviewed on the growth and success of her organization. see more

    Nephron Pharmaceuticals Corporation, located in West Columbia, South Carolina, is a global leader in manufacturing generic respiratory medications and contract manufacturing. Through its innovative approach to sterile manufacturing, Nephron also provides patients access to affordable, high-quality medications. Nephron’s sterile injectables program helps with the drug shortages that hospital across the country are facing.

    Nephron has grown from 400 employees in 2018 to now over 1,000.  A certified woman-owned business, Nephron is recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises.  CEO Lou Kennedy leads the dyunamic organization as well as chairs SCBIO, the life sciences organization for the Palmetto State.  Enjoy this interview with Lou Kennedy, courtesy of MidlandsBiz:  https://whosonthemove.com/lou-kennedy-nephron-pharmaceuticals/

  • Sam Patrick posted an article
    Nephron initiates EDI through Global Healthcare Exchange see more

    Nephron Pharmaceuticals Corporation initiated Electronic Data Interchange (EDI) ordering through the Global Healthcare Exchange, LLC (GHX) platform, accessible immediately.

    Joining GHX allows Nephron customers to purchase products on the FDA drug shortage list in one simple step. This platform enables purchasers to select products from multiple vendors in one place, rather than logging in to the Nephron online ordering system.  Utilizing the GHX cloud-based platform helps to reduce manual work and provides real-time data to view and validate order information. Nephron and its customers are working in real time, using all available data to streamline each process.

    “Nephron is constantly trying to improve the customer experience,” said Hank Jibaja, Chief Information Officer at Nephron. “We believe utilizing the GHX platform will decrease the time required from the hospital or ordering staff.”

    Nephron products including Sodium Bicarbonate, Phenylephrine, Labetalol and more are available for purchase through the GHX platform.

    Hospitals and surgery centers may contact Nephron toll free at 1-800-443-4313, or via email at customerservice@nephronpharm.com.

     

    About Nephron

    Nephron 503B Outsourcing is a division of Nephron Pharmaceuticals Corporation. This division produces pre-filled sterile syringes and IV bags for hospitals and surgery centers across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration as a sterile manufacturer of generic respiratory medications along with an Outsourcing Facility providing equal sterility and quality. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

    About GHX

    Global Healthcare Exchange, LLC (GHX) is a healthcare business and data automation company, empowering healthcare organizations to enable better patient care and maximize industry savings using its world-class cloud-based supply chain technology platform. GHX brings together healthcare providers, manufacturers and distributors in North America, and Europe, who rely on proven healthcare-focused technology and comprehensive data to automate business processes and make more informed, timely and fact-based decisions. Solutions span procurement and accounts payable automation, contract and inventory management, vendor credentialing and management, business intelligence, payment management and other supply chain-related tools and services. For more information, visit www.ghx.com and The Healthcare Hub.

  • Sam Patrick posted an article
    Nephron CEO Lou Kennedy honored with national award see more

    Nephron Pharmaceuticals President and CEO Lou Kennedy was honored on Thursday by the National Association of Manufacturers (NAM) with an award for outstanding leadership in manufacturing.  Ms. Kennedy is also the Board Chair of South Carolina's life sciences organization, SCBIO.

    NAM recognized Kennedy at its Manufacturing Institute’s STEP Ahead Women’s Initiative. One of NAM’s largest annual events, the STEP Ahead Award celebrates the achievements of women in manufacturing who inspire the next generation to follow in their footsteps.

    “Nephron is a global leader in pharmaceutical manufacturing, and I am grateful to NAM for recognizing the great work of our team of professionals that delivers safe, effective and affordable medications to patients across the world,” said Kennedy.

    Nephron is a certified woman-owned business, as recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises. The certification gives Nephron enhanced visibility and a competitive edge.

    Nephron’s workforce is forty-four percent women, holding the majority of all advanced degrees at the company. Additionally, women hold key management roles in various departments throughout Nephron, such as Quality Assurance, Chemistry and Microbiology, Regulatory Compliance, Human Resources, Training, R&D Engineering, and Product Development.

     

    About Nephron

    Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

  • Sam Patrick posted an article
    Nephron Pharmaceuticals continued support of educational opportunities by announcing scholarships see more

    The South Carolina Governor’s School for the Arts and Humanities received a $13,800 gift from Nephron Pharmaceuticals to support meal plan scholarships for Midlands students attending the school’s residential high school program.

    “Nephron Pharmaceuticals Corporation is so proud to support arts education in our state. I have seen first-hand the impact of an arts education on the mind of a scientist, and it’s a beautiful thing. Look at a trained violinist and a pharmaceutical product developer. Both pursuits require repetition, dedication, critical thinking and the ability to solve a problem from a variety of angles,” said Lou Kennedy, CEO of Nephron Pharmaceuticals. “At Nephron, we’re always looking for critical thinkers and problem solvers, and that is why we are so passionate about supporting the arts as well as the sciences. We are proud to be a sponsor the South Carolina Governor’s School for the Arts and Humanities, and I encourage my fellow CEOs to support arts education across our state. We’re playing the long game here, and we aim to win.”

    “While the Governor’s School for the Arts is a state-funded and tuition-free public high school, there are still meal plan fees that would present a financial barrier for many families if it weren’t for the support of our generous individual and corporate donors,” said Dr. Cedric Adderley, S.C. Governor’s School for the Arts and Humanities president. “Thanks to Nephron Pharmaceuticals, our emerging artists can pursue their dreams without worrying about costs.”

    While tuition is free for all students attending for the full school year, about 30 percent of Governor’s School for the Arts students receive financial assistance from the Governor’s School for the Arts Foundation to pay for the $3,500 meal plan each year. This plan includes three meals per day for seven days per week during the nine-month school year. Nephron’s gift will provide meal plan scholarships to four Midlands students during the 2018-2019 school year.

    Currently, 52 of the Governor’s School for the Arts’ 236 high school students are from the Midlands region, including Calhoun, Fairfield, Kershaw, Lexington, Orangeburg, Richland, Saluda, and Sumter counties. These students were selected based on their talents exhibited through a comprehensive application and audition process.

    To learn more about the S.C. Governor’s School for the Arts & Humanities, follow @SCGSAH on social media and visit http://www.scgsah.org.

  • Sam Patrick posted an article
    Nine Nephron employees to earn their Community Pharmacy Technician certificates at no cost... see more

    Nephron Pharmaceuticals Corp. is partnering with Apprenticeship Carolina to provide nine Nephron employees a chance to earn a Community Pharmacy Technician certificate at Midlands Technical College.  Apprenticeship Carolina is a division of the S.C. Technical College SystemRead on for full details.

  • Sam Patrick posted an article
    Nephron announces 5% salary increases thanks to tax cuts law see more

    WEST COLUMBIA, S.C. – Nephron Pharmaceuticals Corporation (Nephron) CEO Lou Kennedy today announced five percent increases for all employees with the exception of commissioned employees.  The raises are a direct result of the Tax Cuts and Jobs Act that was signed into law last week by President Donald Trump.

    “We are excited that the Tax Cuts and Jobs Act has given us an opportunity to recognize their hard work and sacrifices with well-deserved raises”, said Lou Kennedy, CEO of Nephron.

    Elected officials – including The Honorable Henry McMaster, Governor of South Carolina, U.S. Senator Lindsey Graham, Congressman Joe Wilson, state legislators and local elected officials – joined Kennedy and Nephron employees for today’s announcement celebration at the company’s West Columbia headquarters. Both of South Carolina’s U.S. Senators and six of the state’s seven members of the U.S. House of Representatives voted in favor of the Tax Cuts and Jobs Act.

    "I am grateful that the tax cuts House Republicans worked so hard to pass have had an immediate impact in the district,” said Congressman Joe Wilson. “I congratulate Lou and Bill Kennedy, as well as Nephron's entire team, on today’s announcement, and I wish them continued success.”

    Nephron is a manufacturer of respiratory and compounded 503B outsourcing medications that employs 640 people in West Columbia. The company, which launched 34 new products in 2017, recently announced a $12.5 million expansion and expects to add 125 additional employees by June 2018.

    Fifty percent of Nephron employees attended South Carolina universities or technical colleges. Nephron founder Bill Kennedy and CEO Lou Kennedy are University of South Carolina graduates and South Carolinians. The company is part of the life sciences industry in the State.  This industry has a total $11.4 billion annual impact on the State economy.

    For more information about Nephron, visit http://www.nephronpharm.com.

  • Sam Patrick posted an article
    Lou Kennedy, CEO of Nephron Pharmaceuticals, will chair the SC Chamber of Commerce Board for 2018-19 see more

    The South Carolina Chamber of Commerce and the board have selected its newly elected officers and Board of Directors for 2018-2019. Leadership terms for the chamber’s officers and Board of Directors begin on October 1, 2018. Lou Kennedy will be the 2018 – 2019 Chairman.

    Lou Kennedy is President, Chief Executive Officer and owner of Nephron Pharmaceuticals Corporation. She joined Nephron Pharmaceuticals in 2001 and accepted the position of President and Chief Executive Officer in September 2007. Along with her husband Bill, Kennedy helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy. She serves on a variety of business and civic boards.